Clinical stage Leverage the company’s clinical-stage portfolio of ischemia-tolerant progenitor cells and neural progenitor cells to explore partnerships for phase-specific clinical trial collaboration, co-development, or licensing opportunities in ischemic stroke, Alzheimer’s disease, and spinal cord injury.

Manufacturing platform Target their proprietary low-oxygen, low-tension, cGMP manufacturing platform for collaboration on scalable production of allogeneic progenitor cell therapies, including technology licensing, contract manufacturing, or process optimization services.

Strategic leadership Engage with the leadership team and newly appointed CEO to align on strategic partnerships, potential funding rounds, and joint ventures that accelerate late-stage development, manufacturing scale, or commercialization readiness.

Funding and market positioning Position opportunities around their existing modest revenue and $22M funding to pursue grant support, milestone-based collaborations, and low-risk co-investment deals with larger biopharma seeking access to stem cell platforms and unmet medical needs.

Clinical trial expansion Propose sponsored or collaborative trials for IV allogenic mesenchymal stem cells in chronic ischemic stroke and expand to adjacent indications, leveraging their proven trial activity to shorten time-to-enrollment and co-financing patient cohorts.